Patterns of medical practice in cystic fibrosis: Part II. Use of therapies

Pediatric Pulmonology

Volumn 28, Issue 4, 1999, Pages 248-254

  Konstan, Michael W ^a,e   Butler, Steven M ^b   Schidlow, Daniel V ^c   Morgan, Wayne J ^d   Julius, Joanne R ^b   Johnson, Charles A ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GENENTECH INC   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Airway clearance; Anti inflammatory agents; Antibiotic; Bronchodilator; Children; Corticosteroid; Cystic fibrosis; Dornase alfa; Nutritional supplement; Pancreatic enzyme; Treatment

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DIURETIC AGENT; DORNASE ALFA; INSULIN; MUCOLYTIC AGENT; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PANCREAS ENZYME; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGE; ANTIBIOTIC THERAPY; ARTICLE; BRONCHODILATATION; CYSTIC FIBROSIS; DIURETIC THERAPY; ENTERIC FEEDING; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CLEARANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; ORAL DRUG ADMINISTRATION; OXYGEN THERAPY; PARENTERAL NUTRITION; PRIORITY JOURNAL; PSEUDOMONAS; RESPIRATORY TRACT INFECTION; STEROID THERAPY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYSTIC FIBROSIS; DRAINAGE, POSTURAL; EVALUATION STUDIES; FEMALE; HUMANS; MALE; NUTRITION PHYSIOLOGY; PATIENT CARE; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SAMPLING STUDIES;

EID: 0032869672     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199910)28:4<248::AID-PPUL3>3.0.CO;2-N     Document Type: Article

References (21)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis: state of the art. Am J Respir Crit Care Med 1996;154:1229-1256.
2. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996; 335:179-188.
3. World Health Organization. Therapeutic approaches to cystic fibrosis: memorandum from a joint WHO/ICF(M)A meeting. Bull WHO 1994;72:341-352.
4. Ramsey BW, Farell PM, Pencharz P. Nutritional assessment and management in cystic fibrosis; a consensus report. Am J Clin Nutr 1992;55:108-116.
5. Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA, for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Patterns of medical practice in cystic fibrosis: Part I. Evaluation and monitoring of health status of patients. Pediatr Pulmonol 1999;28:242-247.
6. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-734.
7. Konstan MW. Therapies aimed at airway inflammation in cystic fibrosis. In: Fiel SB, editor. Clinics in chest medicine: cystic fibrosis. Philadelphia: W.B. Saunders Co.; 1998. p 505-513.
8. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate- day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-523.
9. Schidlow DV, Taussig LM, Knowles MR. Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1993;15:187-198.
10. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642.
11. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996;110:889-895.
12. Kirchner KK, Khan TZ, Wagener JS, Accurso FJ. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 1996;154: 1426-1429.
13. Wagener JS, Rock MJ, McCubbin MM, Hamilton SD, Johnson CA, Aherns RC, for the Pulmozyme Pediatric Bronchoscopy Study Group. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: A bronchoscopic study. J Pediatr 1998;133:486-491.
14. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
15. Cystic Fibrosis Foundation Patient Registry 1995 Annual Data Report. Bethesda, MD; 1996.
16. Canadian Cystic Fibrosis Foundation. Report of the Canadian Patient Data Registry 1993. Toronto; 1995.
17. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-854.
18. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187-1191.
19. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48:1041-1050.
20. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997;145: 794-803.
21. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL, for the Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.